https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Wed, 25 Aug 2021 11:22:48 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png https://mirror.vjregenmed.com 32 32 https://mirror.vjregenmed.com/video/1iedhmsgcn4-car-t-vs-bites-in-b-cell-malignancies/ Fri, 26 Feb 2021 14:08:22 +0000 http://13.40.107.223/video/1iedhmsgcn4-car-t-vs-bites-in-b-cell-malignancies/ Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, compares CAR T-cells to bispecific T-cell engagers (BiTEs). Firstly, Prof. Subklewe highlights that there are no randomized trials in any disease comparing CAR T-cells to BiTEs. Different parameters can be compared between CAR T-cells and BiTEs, including construct design, manufacturing, and production time. Additionally, data from clinical trials can provide insights into aspects such as safety and efficacy. Compared to CAR-T therapies, the BiTE platform provides an off-the-shelf product with a high safety profile, which are significant advantages. In the future, predictive biomarkers are needed to stratify patients to the safest and most successful treatment option. This interview took place during the 3rd European CAR T-cell Meeting.

]]> https://mirror.vjregenmed.com/video/jcohhit-jzg-liso-cel-for-rr-large-b-cell-lymphoma/ Fri, 26 Feb 2021 14:08:19 +0000 http://13.40.107.223/video/jcohhit-jzg-liso-cel-for-rr-large-b-cell-lymphoma/ Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the recent FDA approval of lisocabtagene maraleucel (liso-cel) for relapsed or refractory (R/R) large B-cell lymphoma. Prof. Jäger considers this approval another milestone in the lymphoma field that now has three CAR-T products available. The approval of liso-cel in Europe is expected soon. This interview took place during the 3rd European CAR T-cell Meeting.

]]>